As a new investor to CU6 this research is amazing, thank you for sharing.
is there answers to your following questions?
1. "Diagnostic agents could receive quick approval - do they need a phase 3 trial?"
Is it possible they could seek approval off early data than recruit the full 383 patients? FDA meeting sounded positive.
2. "Are there any trials pending to be completed between now and Q2 2024?
The Secure Cu64/67 SAR-bisPSMA trial entering Cohort 3 out of 4, 44 patient and obviously results look extremely good thus far even on a single dose of 8GBq, could we assume cohort 4 will be reported well before Q2?
I notice TLX were a $2b Market cap at the time of approval of Illucix, valued on the positive P3 results, however had licensed from Elli Lilly, impacting some of the upside.
-
- There are more pages in this discussion • 244 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$3.91 |
Change
0.020(0.51%) |
Mkt cap ! $1.264B | |||
| Open | High | Low | Value | Volume |
| $3.87 | $4.16 | $3.84 | $22.81M | 5.683M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5599 | $3.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.95 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |